Danny Sullivan

Glasgow

Contributing Editor at Longevity Technology

Contributing Editor at @LongevityTech. Writer, marketer, PR'er, traveller, reader, runner, technolover and lots of other ers...

Featured in: Favicon

longevity.technology Favicon

flipboard.com

Articles

YuvaBio strikes obesity drug discovery deal with Northstrive

1 week ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp Longevity biotech Yuva Biosciences has inked a development and license agreement with Northstrive Biosciences aimed at advancing pharmaceutical therapies for obesity, type 2 diabetes and other cardiometabolic diseases by targeting mitochondrial dysfunction. The agreement provides YuvaBio with upfront and milestone payments as well as royalties on future sales of therapeutic products developed using the identified compounds.
Ventyx touts positive results in Parkinson’s trial

1 week ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp US biotech Ventyx Biosciences has reported encouraging top-line results from a Phase 2a study of its NLRP3 inhibitor in patients with early-stage Parkinson’s disease. While the primary focus was to assess safety and tolerability, the trial also yielded positive data on the drug’s pharmacokinetics, pharmacodynamics and clinical effects.
The stembroids are coming… to transform regenerative medicine

1 week ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp Last month, hot on the heels of the recent Nature paper on replacement as an aging intervention, we came across Israeli biotech RenewalBio, which had just secured funding from longevity investment fund LongGame.
BioAge taps European biobank for human aging data

1 week ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp Longevity biotech BioAge Labs has announced that it will harness molecular data from the HUNT Biobank in Norway to expand the capabilities of its drug discovery platform.
Parallel Bio aims to slash drug discovery by ‘$2 billion and 9 years’

1 week ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp US biotech Parallel Bio has secured $21 million in Series A funding to accelerate development of its human-first approach to drug discovery that seeks to provide a more ethical, accurate and efficient alternative to animal testing.
Fauna Bio launches AI-powered target discovery platform

1 week ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp Longevity biotech Fauna Bio today launched a new AI platform developed to accelerate drug discovery by drawing on the unique biology of highly resilient mammalian species. Dubbed “Fauna Brain”, the platform builds on the company’s original Convergence discovery engine, expanding its capacity to quickly and efficiently identify novel therapeutic targets.
L’Oréal bets on the beauty of longevity science

2 weeks ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp At a suitably glamorous event in Paris this week, global beauty giant L’Oréal unveiled its Longevity Integrative Science initiative. In a shift from cosmetic strategies focused on surface-level corrections, the company says it is now orchestrating its efforts around targeting the root biological causes of aging at the cellular level.
‘Curing age-related diseases is our North Star’

2 weeks ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp One of the most interesting longevity startups to emerge last year was Gordian Biotechnology, which is seeking to transform drug discovery and deliver cures for chronic, age-related diseases. Rather than rely on lab-based screening methods, the San Francisco-based company is leveraging an in vivo platform designed to identify and validate therapies in animal models by mimicking human biology more closely and at scale.
HepaRegeniX commences liver regeneration drug trial

2 weeks ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp German biotech HepaRegeniX has initiated a clinical trial of its liver regeneration drug in patients undergoing partial liver resection due to liver metastases from colorectal cancer. The trial is a key step in evaluating the compound’s safety and therapeutic potential in humans with compromised liver function.
Juvena flexes muscles in $650m collaboration deal with Lilly

2 weeks ago | longevity.technology | Danny Sullivan

Get longevity news first on WhatsApp Longevity biotech Juvena Therapeutics today announced a global licensing and research collaboration with pharma giant Eli Lilly to advance the discovery and development of drug candidates with the potential to treat conditions ranging from frailty to obesity.